Zum Inhalt
Erschienen in:

18.09.2017 | original article

In vitro activity of linezolid alone and combined with other antibiotics against clinical enterococcal isolates

verfasst von: Mahtab Beitdaghar, MSc, Roya Ahmadrajabi, PhD, Afsaneh Karmostaji, PhD, Fereshteh Saffari, PhD

Erschienen in: Wiener Medizinische Wochenschrift | Ausgabe 9-10/2019

Einloggen, um Zugang zu erhalten

Summary

Background

The increasing incidence of antimicrobial resistance has led to research on finding new antimicrobial agents or identifying drug combinations with synergistic effects. Enterococcal infections, particularly those associated with vancomycin-resistant enterococci (VREs), are therapeutic problems. Linezolid (LZD), an oxazolidinone antibiotic, shows good activity against Gram-positive bacteria including enterococci. To avoid the emergence of linezolid-resistant subpopulations and achieve enhanced activity or bactericidal effect, the use of combined therapy has been considered.

Methods

The in vitro activity of LZD in combination with five different antibiotics was evaluated using a microdilution checkerboard method and time-kill study against 12 clinical enterococcus isolates.

Results

With the checkerboard method, LZD plus doxycycline (DX) had the highest frequency among all synergistic combinations. This combination and the one of LZD plus ceftriaxone (CRO) were the most frequent effective combinations against VREs. Time-kill studies using selected synergistic combinations—LZD + DX and LZD + CRO—showed an indifferent interaction. One tested combination of LZD + rifampicin showed antagonism.

Conclusions

Antagonistic interactions in combinations containing LZD are rare. LZD + DX and LZD + CRO may be beneficial in the treatment of VREs. However, more time-kill studies as well as in vivo experiments are required.
Literatur
Dieser Inhalt ist nur sichtbar, wenn du eingeloggt bist und die entsprechende Berechtigung hast.
Metadaten
Titel
In vitro activity of linezolid alone and combined with other antibiotics against clinical enterococcal isolates
verfasst von
Mahtab Beitdaghar, MSc
Roya Ahmadrajabi, PhD
Afsaneh Karmostaji, PhD
Fereshteh Saffari, PhD
Publikationsdatum
18.09.2017
Verlag
Springer Vienna
Erschienen in
Wiener Medizinische Wochenschrift / Ausgabe 9-10/2019
Print ISSN: 0043-5341
Elektronische ISSN: 1563-258X
DOI
https://doi.org/10.1007/s10354-017-0603-1